What is utpatinib?

Upatinib is an orally administered, highly selective JAK1 inhibitor, a small-molecule targeted therapy primarily used to treat various immune-mediated chronic inflammatory diseases.

This drug reduces inflammation by inhibiting the Janus kinase (JAK) signaling pathway, thus modulating an overactive immune system.

Main indications include:

Moderate to severe atopic dermatitis (adults and adolescents aged 12 years and older)

Rheumatoid arthritis (RA)

Psoriatic arthritis (PsA)

Ulcerative colitis (UC) and Crohn's disease (CD)

Spondyloarthritis such as ankylosing spondylitis and non-radiological axial spondyloarthritis

Polyarticular juvenile idiopathic arthritis (pJIA)

Giant cell arteritis

Furthermore, according to recent advancements, utpatinib has been submitted for approval in China for the treatment of non-segmental vitiligo and has been included in the priority review process. The relevant Phase III study has met its primary endpoint, demonstrating significant efficacy.

Dosage and Administration (Common):

The starting dose for most indications is 45 mg once daily for induction of remission; the maintenance dose is usually adjusted to 15 mg once daily; the specific dosage needs to be adjusted according to the disease type, patient response, and physician guidance.

Safety Precautions:

May increase the risk of infection (e.g., tuberculosis, severe bacterial or viral infection); There is a risk of thrombosis (e.g., deep vein thrombosis, pulmonary embolism), especially in patients with cardiovascular risk factors; An increased risk of major adverse cardiovascular events (MACE) has been observed in rheumatoid arthritis patients over 50 years of age with cardiovascular risk; Contraindicated in active tuberculosis, severe infection, severe hepatic impairment, and pregnant women.